T32 Cincinnati Pediatric Clinical Pharmacology Training Program

T32 辛辛那提儿科临床药理学培训计划

• 批准号: 10400764
• 负责人: Laura B Ramsey
• 金额: $ 3.99万
• 依托单位: CINCINNATI CHILDRENS HOSP MED CTR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-16 至 2026-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10400764
• 关键词: Childhood; Clinical Pharmacology; Training Programs

PROJECT SUMMARY This is a competitive renewal application for the continuation of a highly collaborative and successful pediatric clinical pharmacology training program at Cincinnati Children's Hospital Medical Center and the University of Cincinnati. The program will train a new generation of pediatric investigators to assume leadership roles in the application of innovative, high impact quantitative clinical pharmacology approaches to improve the development, rational use and tailoring of new and existing drug therapies for neonates, infants, children, adolescents and young adults. The need for pediatric clinical pharmacology research and training has never been greater. The T32 Training Program in Pediatric Clinical Pharmacology at Cincinnati Children's Hospital Medical Center (CCHMC) is designed specifically to address this critical need. The program is based in the Division of Clinical Pharmacology, which is jointly a unit within the Department of Pediatrics and the University of Cincinnati, College of Medicine (UCCoM). The program outlined in this renewal application draws on strong leadership and a diverse group of well-established faculty mentors actively involved in subspecialty clinical pharmacology research, representing 18 divisions within the Department of Pediatrics, the Departments of Pharmacology & Systems Physiology and Biomedical Informatics at the UCCoM, and the James L. Winkle College of Pharmacy. The program has tremendous institutional support and takes advantage of broad areas of distinction and resources within a uniquely collaborative environment. The T32 training program is innovative and well aligned with the objectives outlined in the program announcement as it: (1) has a focus in early and later phase studies in multiple and diverse pediatric populations through ongoing research collaborations with all major pediatric subspecialties; (2) involves the application and development of innovative quantitative methodologies such as PK/PD modeling and pharmacometrics, quantitative systems pharmacology modeling and simulation and model-informed clinical trial design; (3) is embedded in the institutional and UCCoM pharmacogenetic/genomics research and training endeavors through the Center for Pediatric Genomics; (4) is closely integrated with Bioinformatics and Health Services and Outcomes Research; and (5) can rely on over 10 years of a well-established curriculum after two funding cycles as a successful training program. The program provides a unique training experience to MDs, PharmDs, and PhDs to become the next generation of leaders whose work will advance pediatric clinical pharmacology and to have an extraordinary impact on pediatric therapeutics and health outcomes for children. The program has successfully opened new avenues to enlarge the pool of talented young clinical investigators with a career interest in pediatric therapeutics.

项目摘要 这是一个竞争性更新的应用程序，用于继续高度协作和成功的小儿 辛辛那提儿童医院医疗中心和大学的临床药理学培训计划 辛辛那提。该计划将培训新一代的儿科调查人员在 应用创新的，高影响定量临床药理学方法来改善 针对新生儿，婴儿，儿童，开发，合理使用和裁缝 青少年和年轻人。小儿临床药理学研究和培训的需求从未 更大。辛辛那提儿童医院小儿临床药理学的T32培训计划 医疗中心（CCHMC）专门旨在满足这一关键需求。该程序基于 临床药理学部，该部门是儿科和大学的共同部门 辛辛那提，医学院（UCCOM）。此续订应用程序中概述的程序借鉴了强大的 领导力和一群成熟的教师导师，积极参与专业临床 药理学研究，代表儿科部的18个部门， UCCOM的药理学与系统生理学和生物医学信息学和James L. Winkle 药学院。该计划具有巨大的机构支持，并利用了广泛的领域 在独特的协作环境中的区别和资源。 T32培训计划是 创新性，与计划公告中概述的目标保持一致：（1）重点 通过正在进行的研究对多种和多样的小儿种群进行早期和后期的研究 与所有主要儿科亚专业的合作； （2）涉及应用和开发 创新的定量方法，例如PK/PD建模和药物计量学，定量系统 药理学建模和模拟以及模型信息的临床试验设计； （3）嵌入 机构和UCCOM药物遗传学/基因组学研究和培训通过该中心 小儿基因组学； （4）与生物信息学和卫生服务以及结果研究密切相结合； （5）在两个资金周期成功之后，可以依靠超过10年的公认课程 培训计划。该计划为MDS，PharmDS和Phds提供了独特的培训经验 下一代领导者的工作将推进小儿临床药理学并拥有 对儿童的小儿治疗和健康成果的极大影响。该计划已成功 开辟了新的途径，以扩大有才华的年轻临床调查人员的职业兴趣 小儿疗法。